Clomipramine dose-effect study in patients with depression: Clinical end points and pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 2, 1999, Pages 152-165

  Gram, Lars F ^{a,b,c,d,e,f,g,h,i,j}  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Institute of Medical Biology   (Denmark)

^c HILLERØD HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f FREDERIKSBERG HOSPITAL   (Denmark)

^g Middelfart Hospital   (Denmark)

^h AALBORG UNIVERSITY HOSPITAL   (Denmark)

ⁱ Department of Psychiatry   (Denmark)

^j UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; NORCLOMIPRAMINE;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032793514     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0009-9236(99)90053-x     Document Type: Article

References (46)

1. 1. Höhn R, Gross GM, Gross M, Lasagna L. A double-blind comparison of placebo and imipramine in the treatment of depressed patients in a state hospital. J Psychiatr Res 1963;1:76-91.
2. 2. Gram LF. Plasma level monitoring of tricyclic antidepressant therapy. Clin Pharmacokinet 1977;2:237-51.
3. 3. APA Task Force. Tricyclic antidepressants-blood level measurements and clinical outcome: an APA Task Force report. Am J Psychiatry 1985;142:155-62.
4. 4. Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36:537-47.
5. 5. Bjerre M, Gram LF, Kragh-Sørensen P, Kristensen CB, Pedersen OL, Møller M, et al. Dose-dependent kinetics of imipramine in elderly patients. Psychopharmacology 1981;75:354-7.
6. 6. Sindrup SH, Brøsen K, Gram LF. Nonlinear kinetics of imipramine in low and medium plasma level ranges. Ther Drug Monit 1990;12:445-9.
7. 7. Quitkin FM. Methodology of measuring the efficacy of antidepressants. Psychopharmacology 1992;106:S87-9.
8. 8. Simpson GM, Lee JH, Cuculic Z, Kellner R. Two dosages of imipramine in hospitalized endogenous and neurotic depressives. Arch Gen Psychiatry 1976;33:1093-102.
9. 9. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987;23:164-8.
10. 10. Mendels J, Johnston R, Matters J, Riesenberg R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose response study. Psychopharmacol Bull 1993;29:169-74.
11. 11. Montgomery SA, Pedersen V, Tanghøj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram: a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 1994;9(suppl 1):35-40.
12. 12. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995;38:592-602.
13. 13. Gram LF. Fluoxetine. N Engl J Med 1994;331:1354-61.
14. 14. Preskorn SH, Janicale PG, Davis JM, Ayd FJ. Advances in the pharmacotherapy of depressive disorders. Principles Pract Psychopharmacother 1995;1:1-24.
15. 15. Gram LF. Is there a right dose of psychotropic drugs? A discussion of the methodological problems in clinical dose-effect studies. In: Balant LP, Benitez J, Dahl SG, Gram LF, Pinder RM, Potter WZ, editors. Clinical pharmacology in psychiatry: finding the right dose of psychotropic drugs. Bruxelles: COST B1, European Commission; 1998. p. 1-11.
16. 16. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine - A controlled multicenter study. Psychopharmacology 1986;90:131-8.
17. 17. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-99.
18. 18. Danish University Antidepressant Group. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1993;28:105-16.
19. 19. Balant-Gorgia AE, Balant LP, Genet Ch, Dayer P, Aeschlimann JM, Garrone G. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentration of clomipramine and its major metabolites. Eur J Clin Pharmacol 1986;31:449-55.
20. 20. Nielsen KK, Brøsen K, Gram LF, Danish University Antidepressant Group. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1992;43:405-11.
21. 21. Nielsen KK, Brøsen K, Hansen MGJ, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994;55:518-27.
22. 22. Nielsen KK, Brøsen K, Hansen MGJ, Gram LF. Glucuronidation clearance of 8-hydroxyclomipramine in relation to the sparteine and mephenytoin phenotype. Eur J Clin Pharmacol 1994;47:209-10.
23. 23. Nielsen KK, Flinois JP, Beaune P, Brøsen K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996;277: 1659-64.
24. 24. Jones RB, Tech B, Luscombe DK. Plasma level studies with clomipramine (Anafranil). J Int Med Res 1977;5 (suppl 1):98-107.
25. 25. Delia Corte L, Broadhurst AD, Sgaragli GP, Filippini S, Heeley AF, James HD, et al. Clinical response and tricyclic plasma levels during treatment with clomipramine. Br J Psychiatry 1979;134:390-400.
26. 26. Reisby N, Gram LF, Bech P, Sihm F, Krautwald O, Elley J, et al. Clomipramine: plasma levels and clinical effects. Psychopharmacology 1979;3:341-51.
27. 27. Faravelli C, Ballerini A, Ambonetti A, Broadhurst AD, Das M. Plasma levels and clinical response during treatment with clomipramine. J Affect Dis 1984;6:95-102.
28. 28. Kuss HJ, Jungkunz G. Non-linear pharmacokinetics of chlorimipramine after infusion and oral administration in patients. Prog Neuropsychopharmacol Biol Psychiatry 1986;10:739-48.
29. 29. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
30. 30. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Quantitative rating of depressive states. Acta Psychiat Scand 1975;51:161-70.
31. 31. American Psychiatric Association. Mood disorders. In: Diagnostic and statistical manual of mental disorders. 3rd ed revised. Washington (DC): American Psychiatric Association; 1987.
32. 32. Carney MWP, Roth M, Garside RF. The diagnosis of depressive syndromes and the prediction of ECT response. Br J Psychiatry 1965;111:659-74.
33. 33. Gurney C, Roth M, Garside RF, Kerr TA, Schapina K. Studies on the classification of affective disorder: the relationship between anxiety and depressive illness. Br J Psychiatry 1972;121:162-6.
34. 34. Bech P, Rafaelsen OJ. The use of rating scales exemplified by a comparison of the Hamilton and the Bech-Rafaelsen Melancholia Scale. Acta Psychiat Scand 1980; 62(suppl)285:128-32.
35. 35. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU-side effect rating scale. Acta Psychiat Scand 1987;76(suppl 334):1-100.
36. 36. Nielsen KK, Brøsen K. High performance liquid chromatography of clomipramine and metabolites in human plasma and urine. Ther Drug Monit 1993;15:122-8.
37. 37. Vinks A, Inaba T, Otton SV, Kalow W. Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther 1982;31:23-9.
38. 38. Brøsen K, Otton SV, Gram LF. Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 1985;57: 357-60.
39. 39. Siegel S, Castellan NJ. Non parametric statistics for the behavioral sciences. 2nd ed. New York: McGraw-Hill; 1988. p. 399.
40. 40. Wulff HR, Schlichting P. MEDSTAT Statistical Program, version 2.12. Albertslund, Denmark: Astra Group A/S;1991.
41. 41. Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry 1984;41:782-6.
42. 42. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-95.
43. 43. Pollock BG, Perel MJ, Shostak M, Antelman SM, Brandom B, Kupfer DJ. Understanding the response lag to tricyclics; I: application of pulse-loading regimens with intravenous clomipramine. Psychopharmacol Bull 1986;22:214-9.
44. 44. Pollock BG, Perel JM, Kupfer DJ, Bowler KA, Miewald JM. Early response patterns associated with successful clomipramine treatment. J Clin Psychopharmacol 1993; 13:442-7.
45. 45. Sheiner LB, Stuart LB, Sambol NC. Study designs for dose-ranging. Clin Pharmacol Ther 1989;46;63-77.
46. 46. Balant LP, Benitez J, Dahl SG, Gram LF, Pinder RM, Potter WZ, editors. Clinical pharmacology in psychiatry: finding the right dose of psychotropic drugs. Bruxelles: COST B1, European Commission; 1998. p. 354.